Cargando…

Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies

Polyglutamine (polyQ) diseases are hereditary neurodegenerative disorders caused by an abnormal expansion of a trinucleotide CAG repeat in the coding region of their respective associated genes. PolyQ diseases mainly display progressive degeneration of the brain and spinal cord. Nine polyQ diseases...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Chunchen, Zhang, Shun, Dong, Xiaoyu, Ma, Shuang, Cong, Shuyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962650/ https://www.ncbi.nlm.nih.gov/pubmed/29867345 http://dx.doi.org/10.3389/fnmol.2018.00153

Ejemplares similares

The Emerging Role of microRNAs in Polyglutamine Diseases
por: Dong, Xiaoyu, et al.
Publicado: (2019)

The emerging roles of long non‐coding RNAs in polyglutamine diseases
por: Dong, Xiaoyu, et al.
Publicado: (2021)

Post-translational Modifications and Protein Quality Control in Motor Neuron and Polyglutamine Diseases
por: Sambataro, Fabio, et al.
Publicado: (2017)

MicroRNAs Dysregulation and Metabolism in Multiple System Atrophy
por: Xiang, Chunchen, et al.
Publicado: (2019)

Unraveling the Post-Translational Modifications and therapeutical approach in NSCLC pathogenesis
por: Gulhane, Pooja, et al.
Publicado: (2023)

Skeletal Muscle Pathogenesis in Polyglutamine Diseases
por: Marchioretti, Caterina, et al.
Publicado: (2022)

On the role of RNA binding proteins in polyglutamine diseases: from pathogenesis to therapeutics
por: Conceição, André, et al.
Publicado: (2023)

Bioinformatic gene analysis for potential therapeutic targets of Huntington’s disease in pre-symptomatic and symptomatic stage
por: Xiang, Chunchen, et al.
Publicado: (2020)

Editorial: The role of posttranslational modifications in polyglutamine diseases
por: Weber, Jonasz Jeremiasz, et al.
Publicado: (2023)

Dysregulated transcriptional and post-translational control of DNA methyltransferases in cancer
por: Lin, Ruo-Kai, et al.
Publicado: (2014)

Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases
por: Ryan, Brent J., et al.
Publicado: (2014)

Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer’s disease
por: Mumtaz, Ibtisam, et al.
Publicado: (2022)

Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor
por: Liu, Na, et al.
Publicado: (2022)

Aberrant accumulation of NIK promotes tumor growth by dysregulating translation and post-translational modifications in breast cancer
por: Hayashi, Yusuke, et al.
Publicado: (2023)

The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson’s Diseases
por: Zhang, Jiaming, et al.
Publicado: (2019)

Editorial: Plastid Proteostasis: Relevance of Transcription, Translation, and Post-translational Modifications
por: Alagna, Fiammetta, et al.
Publicado: (2017)

Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets
por: Liu, Ruiqi, et al.
Publicado: (2023)

Oligonucleotide-based strategies to combat polyglutamine diseases
por: Fiszer, Agnieszka, et al.
Publicado: (2014)

Implications of Oxidative and Nitrosative Post-Translational Modifications in Therapeutic Strategies against Reperfusion Damage
por: Buelna-Chontal, Mabel, et al.
Publicado: (2021)

Tubulin Post-translational Modifications: Potential Therapeutic Approaches to Heart Failure
por: Liu, Chang, et al.
Publicado: (2022)

Post-Transcriptional and Post-Translational Modifications in Telomerase Biogenesis and Recruitment to Telomeres
por: Shepelev, Nikita, et al.
Publicado: (2023)

In silico prediction of post-translational modifications in therapeutic antibodies
por: Vatsa, Shabdita
Publicado: (2022)

A survey of protein interactions and posttranslational modifications that influence the polyglutamine diseases
por: Johnson, Sean L., et al.
Publicado: (2022)

A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease
por: Xiang, Chunchen, et al.
Publicado: (2022)

Author Correction: A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease
por: Xiang, Chunchen, et al.
Publicado: (2023)

Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders
por: Manzanza, Nelson de Oliveira, et al.
Publicado: (2021)

Role of Host-Mediated Post-Translational Modifications (PTMs) in RNA Virus Pathogenesis
por: Kumar, Ramesh, et al.
Publicado: (2020)

Targeting Post-Translational Modifications of the p73 Protein: A Promising Therapeutic Strategy for Tumors
por: Omran, Ziad, et al.
Publicado: (2021)

Post-Transcriptional Dysregulation by miRNAs Is Implicated in the Pathogenesis of Gastrointestinal Stromal Tumor [GIST]
por: Kelly, Lorna, et al.
Publicado: (2013)

Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias
por: Buijsen, Ronald A.M., et al.
Publicado: (2019)

Post-Translational Modifications of STING: A Potential Therapeutic Target
por: Kang, Jiaqi, et al.
Publicado: (2022)

Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson’s disease
por: Yoo, Hajung, et al.
Publicado: (2022)

A glance at post-translational modifications of human thyroglobulin: potential impact on function and pathogenesis
por: Tosatto, Laura, et al.
Publicado: (2022)

Regulating tumor suppressor genes: post-translational modifications
por: Chen, Ling, et al.
Publicado: (2020)

DNM3OS regulates GAPDH expression and influences the molecular pathogenesis of Huntington’s disease
por: Dong, Xiaoyu, et al.
Publicado: (2021)

Autophagy and polyglutamine diseases
por: Jimenez-Sanchez, Maria, et al.
Publicado: (2012)

Polyglutamine Repeats in Viruses
por: Schein, Catherine H.
Publicado: (2018)

Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases
por: Takeuchi, Toshihide, et al.
Publicado: (2017)

Myelinating Glia: Potential Therapeutic Targets in Polyglutamine Spinocerebellar Ataxias
por: Putka, Alexandra F., et al.
Publicado: (2023)

Post-Translational Modifications in Transcription Factors that Determine T Helper Cell Differentiation
por: Kim, Hyo Kyeong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s7k1ovtig8gb7tittevrcb4p5v